-
New Insights from KEYMAKER-U03 Substudy 03B on Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
At the 2025 ASCO Genitourinary Cancers Symposium, researchers presented updated findings from the phase 1/2 KEYMAKER-U03 Substudy 03B, evaluating pembrolizumab (pembro) and targeted therapy combinations for previously treated advanced ccRCC.…
-
ASCO GU 2025 | MD Anderson Cancer Center: Should Patients with Kidney or Bladder Cancer Receive Immunoadjuvant Therapy?
Kidney cancer and urothelial carcinoma are among the most common malignancies of the urinary system and are known for their strong immunogenicity. This characteristic theoretically makes them ideal candidates for immune checkpoint inhibitors. However, results from multiple phase III randomized controlled trials (RCTs) have failed to demonstrate a significant overall survival (OS) benefit for immunotherapy…
-
New Insights into Young-Onset Bladder Cancer
A groundbreaking genomic study on clinically advanced urothelial bladder cancer (CAUBC) in young-onset bladder cancer (YOUC) patients is reshaping our understanding of age-related tumor biology. Analyzing 9,411 cases, researchers discovered distinct genetic and mutational differences between younger (50) patients, revealing key insights that could transform treatment strategies.
-
Low-Dose Aspirin Cuts Colorectal Cancer Recurrence by 50%: Breakthrough Findings from the ALASCCA Trial
Colorectal cancer (CRC) remains a significant global health burden, with recurrence being a major concern even after standard treatment. The ALASCCA trial, a biomarker-driven randomized study, explored the role of…
-
ASCO GU 2025 | An Alternative ADT Option for Patients with Metastatic Prostate Cancer: Transdermal Estrogen
Androgen deprivation therapy (ADT) remains the cornerstone treatment for patients with metastatic prostate cancer. However, it is frequently associated with adverse effects such as vasomotor symptoms, including hot flashes, fatigue, and bone density loss, which significantly impact patients’ quality of life. The rapid advancements in therapeutic strategies for advanced prostate cancer have led to investigations…
-
Exploring New Ground: Bispecifics and Novel Checkpoint Inhibitors in Pancreatic Cancer Therapy
Monoclonal Antibodies in PDAC Monoclonal antibodies targeting key oncogenic pathways have shown potential in PDAC treatment. Late-stage trials combining monoclonal antibodies with chemotherapy have demonstrated varied efficacy. In the GLEAN…
-
ASCO GI 2025 | Dr. Jin Li: A New Era for Chemotherapy as the First Oral Paclitaxel Demonstrates Non-Inferiority to Intravenous Administration
The 2025 ASCO Gastrointestinal Cancers Symposium (ASCO GI) took place from January 23 to 25 in San Francisco, bringing together the latest advancements in digestive tract oncology. Paclitaxel remains one of the most important chemotherapeutic agents for gastric cancer treatment. However, the traditional intravenous (IV) formulation has long been associated with significant adverse effects. Chinese…
Connecting Medical Expertise through Media
